• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chile's plans to create drug regulatory agency

Chile's plans to create drug regulatory agency

May 9, 2011
CenterWatch Staff

The Chilean parliament will examine legislation for a national medicines agency, which is good news for global drugmakers, according to Pharma Times.

Health Minister Jaime Manalich said he is sending legislative proposals to parliament to create the Agencia Nacional de Medicamentos (Anamed), which will take over drug regulatory responsibilities from the National Institute of Public Health (ISPCH).  One important responsibility of the new agency will be enforcement of bioequivalence requirements—which will monitor manufacturing of “me-too” drugs.

Anamed will be particularly positive for international drugmakers, "which have been involved in long judicial battles against local manufacturers of 'me-too' drugs without bioequivalence accreditation," note analysts at IHS Global Insight.

The lack of effective patent enforcement in Chile and failure to adequately implement data protection continue to be major issues for U.S. drugmakers, who recently requested the U.S. Trade Representative (USTR) that Chile should remain on the US Priority Watch List of intellectual property rights (IPR) transgressors. Chile does appear on the Priority Watch List in the USTR's newly-published 2011 Special 301 Report on IPR, which says that “the U.S. urges Chile to provide adequate protection against unfair commercial use, as well as unauthorized disclosure, of undisclosed test and other data generated to obtain marketing approvals for pharmaceutical products." 

Other areas of responsibility for Anamed potentially include: oversight of GMP, with a goal of accrediting at least 50% of manufacturers operating in the country; establishing an average 152 days for the registration of new drug products and 125 days for similar products;  improving pharmacovigilance; creating a framework for drug trials in humans; strengthening cooperation with other Latin American drug regulators such as Argentina's Anmat and Brazil's Anvisa; and developing international partnerships in both the public and private sectors.

 

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing